We’re excited to announce that we’ve embarked on a three-year equine fertility study aimed at establishing our Felix™ device as a leading technology for equine sperm selection. This study is set to open up significant commercial opportunities within the next 12 months.
In collaboration with the University of Newcastle and EquiBreedUK Ltd, and with the support of top Thoroughbred stud farms, we’re taking major steps toward transforming the way equine breeders manage fertility. Our goal is to offer a cutting-edge solution for equine sperm selection that can be quickly adopted across the industry.
Study Focus
Sperm Isolation and Oxidative Stress Testing: The Felix™ device will be evaluated for its ability to isolate high-quality sperm, which is critical for successful artificial insemination (AI). We’ll also be testing oxidative stress levels in both thoroughbred and non-thoroughbred horses using our RoXsta™ technology. This could be a game-changer for monitoring fertility and health, as we explore how stressors like transportation, heat, and exercise impact reproduction.
Market Readiness: We expect the results of this study to confirm Felix™ as an effective tool for equine sperm selection, setting us up to launch the product to over 4,000 horse breeders worldwide. What’s particularly exciting is that Felix™ won’t need any significant modifications before it’s ready for global distribution. Our timeline targets the release of publishable results within 12 months, giving us a solid foundation to begin marketing and sales efforts soon after.
Synergies with Bovine Research: This equine study will also provide valuable insights that will support our ongoing research into bovine fertility. We’re excited to see how these synergies can further accelerate our progress in the broader animal fertility market.
Why This Matters
The global Equine Artificial Insemination (AI) market was valued at USD 681.1 million in 2023, with projected annual growth of 5.7% through 2032. This growing market provides a huge opportunity for us, as more breeders turn to advanced reproductive technologies to enhance the genetics of their horses. Felix™ is perfectly positioned to address this need by offering a more efficient and effective sperm selection method
What’s Next?
We’re actively seeking a global distributor for Felix™, and we’ve already generated leads through our collaboration with the University of Newcastle. Once the study results are in, we anticipate launching Felix™ for non-thoroughbred breeders within the next year, with direct sales opportunities expected to follow quickly.
Final Thoughts
Our goal with this equine fertility study is to accelerate the commercialisation of Felix™ and expand our impact in the animal fertility space. We believe this will not only benefit breeders but also deliver significant value to our investors. As always, we’ll keep you updated as we move forward with the study and finalise our plans for commercial rollout.
This is just one of many exciting steps we’re taking to push the boundaries of reproductive biotechnology, and we’re eager to see where it leads
